September 23, 2015

The launch comes after Camber’s parent company, Hetero Labs received final approval from the Food and Drug Administration.

August 20, 2015

Marketing efficiency can vary significantly across brands and across channels, according to a recent report analyzing the digestive category conducted by Competitive Promotion Report.

August 20, 2015

Since the launch of Nexium 24HR in May of 2014, the brand has generated approximately $300 million, “making it one of the largest and most successful Rx-to-OTC switches,” Ian Read, Pfizer chairman and CEO, recently told analysts.

August 20, 2015

The big story in the digestives space continues to be the switch and launch of Pfizer’s Nexium 24HR. For the 52 weeks ended June 14, sales of Nexium 24HR across total U.S. multi-outlets reached $278.7 million and are still climbing, according to IRI.

August 6, 2015

Mylan on Wednesday announced the U.S. launch of its generic version of Nexium (esomeprazole magnesium delayed-release capsules) in 20- and 40-mg dosage strengths.

March 4, 2015

Almost half of all circular ads in support of a digestive remedy promote an antacid tablet. 

January 27, 2015

The Food and Drug Administration on Monday announced approval for the first generic version of Nexium (esomeprazole magnesium delayed-release capsules), which are used to treat gastroesophageal reflux disease in adults and children ages 1 year and older.

January 27, 2015

Teva Pharmaceutical Industries announced that the Food and Drug Administration approved the company’s first generic Nexium delayed-release tablets in the United States.

October 15, 2014

The big story in the digestives space is the switch and launch in May of Pfizer’s Nexium 24HR. In a little more than 10 weeks on the shelf, the brand has generated $53.6 million in sales across total U.S. multi-outlets for the 52 weeks ended Aug. 10, according to IRI. 

August 21, 2014

There are a number of growth drivers across the digestives space, starting with the biggest proton-pump inhibitor to make its way from behind the pharmacy bench to over-the-counter aisles since the original “Purple Pill” was switched in 2003.

August 20, 2014

In May 2014, Pfizer introduced Nexium 24HR, one of the top-selling acid blockers, over the counter in the United States.

August 20, 2014

Pfizer successfully switched Nexium to over-the-counter in late May, and with that brought a $6 billion book of prescription business to antacid aisles, according to IMS Health data compiled over 2012.

May 27, 2014

Pfizer on Tuesday announced the introduction in the United States of over-the-counter Nexium 24HR, making the "Purple Pill" available for the treatment of frequent heartburn in adults.

May 6, 2014

Pfizer's Nexium 24HR will launch May 27, Pfizer reported in a conference call Monday.

March 31, 2014

The Food and Drug Administration on Friday approved over-the-counter Nexium 24HR (esomeprazole 20mg), Pfizer announced.

March 20, 2014

AstraZeneca on Wednesday launched Nexium Direct, a program that provides eligible patients the option of having brand-name Nexium delivered directly to their home.

January 6, 2014

Amneal Pharmaceuticals has launched an authorized generic version of a recently launched drug for gastroesophageal reflux disease, the company said.

December 26, 2013

Heading into 2014, there are a number of growth drivers across the digestives space.

December 23, 2013

A federal court decision paves the way for Amneal Pharmaceuticals and its South Korean partnering company to market a drug for treating gastroesophageal reflux disease, the companies said Monday.

December 17, 2013

Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.

December 2, 2013

Pfizer on Monday announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.

September 10, 2013

What a difference a year will make. While sales of antacid tablets were down 1.3% to $2 billion for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI, the entire category ought to have made a significant resurgence by this time next year.

August 8, 2013

Despite significant challenges coming from private label, Procter & Gamble is still attempting to innovate the No. 1 brand in all of digestives — Prilosec OTC.

June 5, 2013

South Korean drug maker Hanmi Pharmaceutical Co. and U.S. partner Amneal Pharmaceuticals have made an agreement in federal court concerning a generic heartburn drug.